Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
29 results
D1.342 - Therapeutic Potential of LCAA-PSF in Atopic Dermatitis: Insights from an MC903-Induced Mouse Model
D1.349 - Age-related fungal molecular clusters revealed by allergen chip assay in Eastern France
D1.352 - Assessment of the Efficacy of Mepolizumab in Modulating Disease Activity in Eosinophilic Granulomatosis with Polyangiitis: A 12-Month Analysis Evaluating the Birmingham Vasculitis Activity Score
D1.343 - Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis
D1.344 - Role of nodular lymphoid hyperplasia as immunologic precursor of IBD development in patients with IBS-like symptoms: an observational, ambispectic, muliticenter study “The NILO study”
D1.345 - Biologic Agents in Neurosarcoidosis: Efficacy and Future Perspectives from a Single-Center Cohort Study
D1.346 - Immunology and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers in stratifying disease risk and severity for precision medicine
D1.347 - Biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms
D1.350 - A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes
D1.351 - The impact of Lactobacillus on the expression of NLRP3, IL-1β and HMGB1 in women with endometriosis associated infertility
D1.353 - When eosinophils surpass the limits without a known cause
D1.355 - Impact of mesothelin in women with endometriosis
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download